A Phase IIIb Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Trial Profile

A Phase IIIb Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Erlotinib (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 24 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 08 Jan 2008 Status changed from recruiting to in progress.
    • 19 Aug 2007 Status changed from in progress to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top